Nutrient weight against sarcopenia: regulation of the IGF-1/PI3K/Akt/FOXO pathway in quinoa metabolites.

Pei-Jie Liu, Yu-Shi Hu, Min-Jia Wang, Liang Kang

Journal: Current opinion in pharmacology 2021;61():136-141

PMID: 34801804

Abstract

Sarcopenia is characterized by the loss of muscle mass and strength, and one of its major molecular mechanisms is muscle protein turnover. Quinoa, the grain-like food crop, is a health nutrient used to treat diseases that predispose individuals to muscle wasting, including cardiovascular disorders, diabetes mellitus, and cancer. Quinoa secondary metabolites have recently been demonstrated to regulate protein turnover (including protein synthesis and degradation), a main biological process within muscle cells, through diverse signals (such as the p38 MAPK, TNF-α, and IGF-1/PI3K/Akt/FOXO pathways). Here, we describe how quinoa functions in the main pathway of protein synthesis and degradation, screen promising pharmacological components in nutritional applications, and provide guidance for the effects of quinoa products in sarcopenia.

Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Address: School of Sports Medicine and Health, Chengdu Sport University, Chengdu, China.; School of Sports Medicine and Health, Chengdu Sport University, Chengdu, China; Institute of Sports Medicine and Health, Chengdu Sport University, Chengdu, China.; Institute of Sports Medicine and Health, Chengdu Sport University, Chengdu, China. Electronic address: [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.